ATLANTA, June 4, 2014 /PRNewswire/ -- Avion Pharmaceuticals, a specialty pharmaceutical company, recently announced its involvement in the Jefferies 2014 Global Healthcare Conference, a four-day global meeting of healthcare industry executives and investors taking place in New York City from June 2-5, 2014.
The 2014 Global Healthcare Conference draws 2,500 attendees from more than 300 participating companies and features an extensive range of public & private healthcare companies across the biopharmaceuticals, life sciences, healthcare services, healthcare IT and medical technology sectors. This global gathering of leading executives, institutional investors, private equity investors and venture capital firms will address near- and long-term investment opportunities and discuss the mechanisms driving healthcare in the U.S. and internationally.
"We are pleased to have Avion participate in this important corporate event," stated Mike Sullivan, President of Avion Pharmaceuticals. "The ability to interact with the global business community focused on the healthcare industry sector will provide Avion exposure and access to new and exciting opportunities that will benefit our ongoing growth."
Avion CEO Mark Pugh added, "Avion is fortunate to partner with Jefferies. They have provided more than 50 years of deep-sector expertise across a full range of products and services. The global healthcare conference will provide profound learning and insight for Avion's leadership team."
Jefferies, LLC, is an international company providing expertise and execution to investors, companies and government entities offering a full range of products and services in investment banking, equities, fixed income, commodities and wealth management in the Americas, Europe and the Middle East and Asia.
About Avion Pharmaceuticals, LLC.
Avion Pharmaceuticals, LLC., is a Specialty Pharmaceutical company formed to develop and market a portfolio of innovative products in the Women's Heath and Dermatology therapeutic areas. Avion Pharmaceuticals focuses on identifying opportunities to acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfill unmet medical needs. For additional information about Avion Pharmaceuticals please contact the company at 678-325-5188.
SOURCE Avion Pharmaceuticals, LLC